EverSource Wealth Advisors’s Vaxcyte PCVX Stock Holding History

EverSource Wealth Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.7K	Sell	735 -513	-41%	-$27.9K	﹤0.01%	1879
2026 Q1	$72.5K	Buy	1,248 +507	+68%	+$27.5K	﹤0.01%	1632
2025 Q4	$34.2K	Buy	741 +184	+33%	+$8.23K	﹤0.01%	2015
2025 Q3	$20.1K	Buy	557 +49	+10%	+$1.62K	﹤0.01%	2351
2025 Q2	$16.5K	Buy	508 +439	+636%	+$14.4K	﹤0.01%	2449
2025 Q1	$2.61K	Buy	69 +18	+35%	+$1.44K	﹤0.01%	2806
2024 Q4	$4.17K	Buy	51 +26	+104%	+$2.58K	﹤0.01%	2427
2024 Q3	$2.86K	Sell	25 -1	-4%	-$90	﹤0.01%	2422
2024 Q2	$2.05K	Buy	26 +7	+37%	+$476	﹤0.01%	2540
2024 Q1	$1.15K	Sell	19 -175	-90%	-$12.1K	﹤0.01%	2539
2023 Q4	$12.2K	Buy	194 +164	+547%	+$8.52K	﹤0.01%	1473
2023 Q3	$1.53K	Buy	30 +1	+3%	+$49	﹤0.01%	2088
2023 Q2	$1.45K	Buy	+29	New	+$1.38K	﹤0.01%	2110

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

EverSource Wealth Advisors's PCVX Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Vaxcyte (PCVX) stake by 41% in Q2 2026, selling an estimated $27.9K and leaving 735 shares worth $42.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1879.

EverSource Wealth Advisors first reported a position in PCVX in Q2 2023 and has held it in 13 quarters since. The position peaked at $72.5K in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

EverSource Wealth Advisors held 735 shares of Vaxcyte worth $42.7K as of Q2 2026.
EverSource Wealth Advisors sold 513 Vaxcyte shares in Q2 2026, an estimated $27.9K.
Vaxcyte made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #1879 holding.
EverSource Wealth Advisors first reported a position in Vaxcyte in Q2 2023 and has held it in 13 quarters since.
EverSource Wealth Advisors's Vaxcyte position peaked at $72.5K in Q1 2026.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.